Crossmark

Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?

Crossref DOI link: https://doi.org/10.1007/s12288-025-02045-4

Published Online: 2025-05-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yıldız, Şeyma https://orcid.org/0000-0001-5942-2361
Demirezen, Asil https://orcid.org/0009-0004-4449-8266
Yeğin, Zeynep Arzu https://orcid.org/0000-0002-0212-9663
Yağcı, Münci https://orcid.org/0000-0002-0458-2920
Özkurt, Zübeyde Nur https://orcid.org/0000-0001-9834-6058
License Information

Text and Data Mining valid from 2025-05-28

Version of Record valid from 2025-05-28
More Information

Article History

Received: 28 October 2024

Accepted: 6 May 2025

First Online: 28 May 2025

Declarations

:

: The authors declare that they have no conflict of interest.